This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pui CH, Relling MV, Downing JR . Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535–1548.
Stock W, Luger SM, Advani AS, Geyer S, Harvey RC, Mullighan CG et al. Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. intergroup trial C10403. Blood 2014; 124: 796.
Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147–156.
DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007; 109: 5136–5142.
Bakr M, Rasheed W, Mohamed SY, Al-Mohareb F, Chaudhri N, Al-Sharif F et al. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012; 18: 1897–1904.
Reddy H, Duffy A, Holtzman NG, Emadi A . The role of β-elimination for the clinical activity of hypomethylating agents and cyclophosphamide analogues. American Journal of Cancer Therapy and Pharmacology 2016; 3: 1–8.
Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106: 3760–3767.
McCormack MP, Shields BJ, Jackson JT, Nasa C, Shi W, Slater NJ et al. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL. Blood 2013; 122: 2093–2103.
Bhatnagar B, Duong VH, Gourdin TS, Tidwell ML, Chen C, Ning Y et al. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymphoma 2014; 55: 1533–1537.
Yánez L, Bermúdez A, Richard C, Bureo E, Iriondo A . Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia. Leukemia 2009; 23: 1342–1343.
Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR et al. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol 2014; 89: 889–895.
Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157–163.
Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet 2014; 46: 364–370.
Hogan LE, Meyer JA, Yang J, Wang J, Wong N, Yang W et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 2011; 118: 5218–5226.
Lu BY, Thanawala SU, Zochowski KC, Burke MJ, Carroll WL, Bhatla T . Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. Leuk Lymphoma 2016; 57: 1938–1941.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
El Chaer, F., Holtzman, N., Binder, E. et al. Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL. Bone Marrow Transplant 52, 1583–1584 (2017). https://doi.org/10.1038/bmt.2017.191
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.191
This article is cited by
-
Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia
Bone Marrow Transplantation (2023)
-
Nelarabine
Reactions Weekly (2017)